Clinical commissioning policy: obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

Document first published:
Page updated:
Publication type:

Obinutuzumab is not recommended to be available as a routine commissioning treatment option in refractory systemic lupus erythematosus (SLE) within the criteria set out in this document.